Claudek,just my thoughts ,perhaps your right ,for mine ,possibly all options are still on the table ,licensing agreement and or T/O,and it’s currently a game of tit for tat between big pharma(competitive tension),mark eluded to this in one his most recent presentations,when he mentioned “T/O or licensing agreement.I tend to lean on the side of licensing agreement ,”significant increase to out trials program”.
Ann: Immutep Corporate Presentation, page-17
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.015(4.92%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 32.5¢ | 30.0¢ | $1.168M | 3.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 148547 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 51809 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |